NEW YORK, Jan. 28, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Realty Income Corporation (NYSE:O), United Therapeutics Corporation (NASDAQ:UTHR), NxStage Medical, Inc. (NASDAQ:NXTM), PTC Therapeutics, Inc. (NASDAQ:PTCT), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), and Owens & Minor, Inc. (NYSE:OMI), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
O DOWNLOAD: http://MarketSourceResearch.com/register/?so=O
UTHR DOWNLOAD: http://MarketSourceResearch.com/register/?so=UTHR
NXTM DOWNLOAD: http://MarketSourceResearch.com/register/?so=NXTM
PTCT DOWNLOAD: http://MarketSourceResearch.com/register/?so=PTCT
AVEO DOWNLOAD: http://MarketSourceResearch.com/register/?so=AVEO
OMI DOWNLOAD: http://MarketSourceResearch.com/register/?so=OMI
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Market Source Research, available for free download at the links above, examine Realty Income Corporation (NYSE:O), United Therapeutics Corporation (NASDAQ:UTHR), NxStage Medical, Inc. (NASDAQ:NXTM), PTC Therapeutics, Inc. (NASDAQ:PTCT), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), and Owens & Minor, Inc. (NYSE:OMI) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed January 24th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
REALTY INCOME CORPORATION (O) REPORT OVERVIEW
Realty Income's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Realty Income reported revenue of $338.08MM vs $306.92MM (up 10.15%) and analysts estimated basic earnings per share $0.34 vs $0.32 (up 6.25%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Realty Income reported revenue of $1,215.77MM vs $1,103.17MM (up 10.21%) and analysts estimated basic earnings per share $1.10 vs $1.13 (down 2.65%). Analysts expect earnings to be released on February 20th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.76. The estimated EPS forecast for the next fiscal year is $3.30 and is expected to report on February 20th, 2019.
To read the full Realty Income Corporation (O) report, download it here: http://MarketSourceResearch.com/register/?so=O
-----------------------------------------
UNITED THERAPEUTICS CORPORATION (UTHR) REPORT OVERVIEW
United Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, United Therapeutics reported revenue of $412.70MM vs $445.50MM (down 7.36%) and analysts estimated basic earnings per share $2.44 vs $6.37 (down 61.70%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, United Therapeutics reported revenue of $1,725.30MM vs $1,598.80MM (up 7.91%) and analysts estimated basic earnings per share $9.50 vs $16.29 (down 41.68%). Analysts expect earnings to be released on February 20th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $2.06. The estimated EPS forecast for the next fiscal year is $8.85 and is expected to report on February 20th, 2019.
To read the full United Therapeutics Corporation (UTHR) report, download it here: http://MarketSourceResearch.com/register/?so=UTHR
-----------------------------------------
NXSTAGE MEDICAL, INC. (NXTM) REPORT OVERVIEW
NxStage Medical's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, NxStage Medical reported revenue of $108.12MM vs $97.30MM (up 11.13%) and analysts estimated basic earnings per share $0.01 vs -$0.14. For the twelve months ended December 31st, 2017 vs December 31st, 2016, NxStage Medical reported revenue of $393.94MM vs $366.38MM (up 7.52%) and analysts estimated basic earnings per share -$0.22 vs -$0.07. Analysts expect earnings to be released on February 15th, 2019. The report will be for the fiscal period ending December 31st, 2018. The estimated EPS forecast for the next fiscal year is $0.22 and is expected to report on February 15th, 2019.
To read the full NxStage Medical, Inc. (NXTM) report, download it here: http://MarketSourceResearch.com/register/?so=NXTM
-----------------------------------------
PTC THERAPEUTICS, INC. (PTCT) REPORT OVERVIEW
PTC Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, PTC Therapeutics reported revenue of $53.59MM vs $41.85MM (up 28.05%) and basic earnings per share -$1.06 vs -$0.82. For the twelve months ended December 31st, 2017 vs December 31st, 2016, PTC Therapeutics reported revenue of $194.39MM vs $82.71MM (up 135.04%) and analysts estimated basic earnings per share -$2.02 vs -$4.17. Analysts expect earnings to be released on March 5th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.03. The estimated EPS forecast for the next fiscal year is -$2.86 and is expected to report on March 5th, 2019.
To read the full PTC Therapeutics, Inc. (PTCT) report, download it here: http://MarketSourceResearch.com/register/?so=PTCT
-----------------------------------------
AVEO PHARMACEUTICALS, INC. (AVEO) REPORT OVERVIEW
AVEO Pharmaceuticals' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, AVEO Pharmaceuticals reported revenue of $2.47MM vs $4.61MM (down 46.53%) and analysts estimated basic earnings per share -$0.18 vs -$0.22. For the twelve months ended December 31st, 2017 vs December 31st, 2016, AVEO Pharmaceuticals reported revenue of $7.58MM vs $2.52MM (up 201.35%) and analysts estimated basic earnings per share -$0.61 vs -$0.39. Analysts expect earnings to be released on March 12th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.08. The estimated EPS forecast for the next fiscal year is -$0.28 and is expected to report on March 12th, 2019.
To read the full AVEO Pharmaceuticals, Inc. (AVEO) report, download it here: http://MarketSourceResearch.com/register/?so=AVEO
-----------------------------------------
OWENS & MINOR, INC. (OMI) REPORT OVERVIEW
Owens & Minor's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Owens & Minor reported revenue of $2,464.88MM vs $2,333.96MM (up 5.61%) and analysts estimated basic earnings per share -$0.01 vs $0.18. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Owens & Minor reported revenue of $9,318.28MM vs $9,723.43MM (down 4.17%) and analysts estimated basic earnings per share $1.20 vs $1.76 (down 31.82%). Analysts expect earnings to be released on February 13th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.35. The estimated EPS forecast for the next fiscal year is $1.07 and is expected to report on February 13th, 2019.
To read the full Owens & Minor, Inc. (OMI) report, download it here: http://MarketSourceResearch.com/register/?so=OMI
-----------------------------------------
ABOUT MARKET SOURCE RESEARCH
Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.
REGISTERED MEMBER STATUS
Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com
© 2019 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.